Original contains color plates: All DTIC reproductions will be in black and white. Estrogen (E2) is required for the development of breast cancer, but there are few animal models to study its mechanism of action in vivo.
Estrogen (E2) is required for the development of breast cancer, but there are few animal models to study its mechanism of action in vivo. We hypothesize that the timing of estrogen receptor a (ERa) action is crucial in normal mammary gland development and tumorigenesis.
Therefore, a transgenic mouse model with a regulatable ERa is being generated.
In vitro, a mutant ERa (525L) has a severely attenuated response to endogenous estradiol (E2) but a wild-type (WT) response to diethylstilbestrol (DES).
E2 binding was decreased in 525L (Kd 12.5nM) compared with WT (Kd O.lnM), but DES binding was comparable (Kd 0.04 and 0.03nM respectively).
Gene targeting was used to insert 525L into the WT ER gene.
Screening for the construct in 350 ES cell clones is underway. The mutant 525L ERa discrimination in transcriptional response to DES and E2 appears to result from differences in ligand binding affinity.
The resultant transgenic mouse will enable us to study how the timing of ER activation modulates normal mammary maturation and the development of mammary cancers. The mutant ER mice are uniquely suited to study the role of ligand independent ER activation in vivo, and will also be usefiil in studying reproductive tract development and behavior.
SUBJECT TERMS

BODY
Task 1.
Transgenic mice expressing only a mutant ER with ligand discrimation will be developed, (months 1 -12) a) Mouse ER genomic DNA will be cloned. A targeting construct (8 to 10 kb) will be generated.
Construct (Work performed at University of Chicago):
The 15 kb construct used in subsequent experiments is consisting of the PGK promoter, neo open reading frame and poly A tail sequence, is found approximately 1.2 kb downstream of exon 9 in reverse orientation at a BamHI site found in the genomic DNA. For removal with Cre-recombinase, the Neo cassette was flanked by LoxP sites (Figure 1 ). This construct was provided by our collaborators Deborah Swope and Ken Korach^ Approximate restriction enzyme sites and distances between sites were determined by sequencing and restriction enzyme/DNA gel analysis.
Mutagemsis (Work performed at University of Chicago):
Mutagenesis was performed by PCR using Qiagen's site directed mutagenesis kit. Three rounds of mutagenesis were performed following the kit's instructions. Briefly, primers were designed using MacVector to 1) alter the coding sequence at codon 525 to convert glycine (G) to leucine (L). 2) Create a novel Xbalsite in exon 9 while maintaining the amino acid sequence. 3) Remove a nucleotide insertion event (4G->3G) near the end of exon 9 that was discovered upon sequencing. Each round of mutagenesis was performed as directed, with the PCR extension time expanded to accommodate 15 kb.
Ligand binding characterization of525L mutation (Work performed at Medical College of Wisconsin):
We hypothesized that the ligand discrimination of 525L is a result of differences in binding affinity between E2 and DBS present in 525L and not in WT ERa. Charcoal assays were used to determine saturation binding characteristics. The 525L mutant receptor had a Kd of 0.03nm with DES, compared with a Kd of 12.5nm with E2. In contrast, the WT receptor had a Kd of 0.04 with DES, and a Kd of 0.12nm withE2.
b) Mice transgenic and homozygous for mutant ER will be generated (Work performed at Medical College of Wisconsin). 1) Homologous recombination in embryonic stem cells. 2 x 10* embryonic stem cells (D3) were electroporated with 100 microgram of linearized targeting construct. Transfected cells were plated onto 20 dishes containing a confluent monolayer of neomycin-resistant, growth-inactivated (gamma-irradiation) embryonic fibroblasts. 24h after transfection, the growth media was supplemented with G418 (final concentration 200 microgram/ml) and Gancyclovir (final concentration 1 micromolar). After 9 days, approximately 350 resistant colonies were isolated and individually expanded for preparation of fi-ozen stocks and for preparation of genomic DNA.
2) PCR Strategy for detection of homologous recombination in ES cell clones (Work performed at University of Chicago):
For identifying positive ES clones that have replaced the endogenous estrogen receptor sequence with the altered construct, a PCR strategy was designed. Primers (external) were designed (MacVector) to bind to a region near the end of the neo open reading frame and to a region just outside of the construct (sequence from BLAST mtrace database) (Figure 2) . If the construct is incorporated into the mouse genome at the appropriate location, a 4.3 band will be generated. In addition, a primer was designed to a region to the end of the construct (Figure 2 ). This internal primer (4.0 kb band) will allow us to confirm the validity of PCR as well as identify PCR conditions before ES cells are electroporated.
(The following work performed at Medical College of
Wisconsin) The PCR strategy was tested using genomic DNA from a positive ES clone (using the same targeting construct but with a different mutation) identified by our collaborator, Debra Swope and Ken Korach. However, we were unable to detect any PCR product with either the internal or external primers fi-om the ES cell clone, though the internal primer set amplified the construct DNA without difficulty. We tried varying conditions, Taq enzymes, alternate primer sets, increasing the amount of DNA template, all to no avail. We suspect our failure in the ES cell DNA template is due to 1) the small amount of starting template and resultant small amount of product that could not be detected by ethidium bromide staining, and 2) inefficiency of amplification due to the length of PCR product (~ 4000 bp) required to confirm homologous recombination. At this point, we are reluctant to use labeled probes for detection of PCR product due to potentially increasing the chance of identifying false positive samples from contamination. Therefore, we have changed to a Southern hybridization strategy for detection of homologous recombination in ES cells. figure 3 ) were prepared using random primer reactions with Klenow enzyme and 32P-dATP. Sephadex G50 colunms were used to separate free nucleotides from the probe, and specific activity was calculated. Prehybridization for 30 minutes was followed by hybridization with the probe (1 x lO' cpm of probe /ml of hybridization solution) overnight at 68°C. Serial washes at 65°C at 2X SSC (twice) and 0.2X SSC (twice) were followed by overnight exposure to film at -80°C and processing. 
3) Southern hybridization for detection of homologous recombination ofES cell clones (Workperformed at Medical
CONCLUSIONS
Over the first year of this award, we have made good progress toward creating the transgenic mouse model with a regulatable ER that was proposed for this project. We anticipate having transgenic animals within the next 6 months. We will then be able to characterize the phenotype, followed by experiments to determine how the timing of ER action affects mammary gland maturation and modulates manunary tumorigenesis and latency in models of genetically and chemically induced mammary cancers. With the widespread clinical use of ER Hgands, detailed understanding of ER action is increasingly important. This model will allow us to manipulate ER transcriptional activity in-vivo during different developmental stages, and will add significantly to current knowledge on ligand-activated and ligand-independent ER action. Results fi"om our proposal on how the timing of ER activation modulates normal mammary maturation and the development of mammary cancers will likely lead to determining susceptible periods for treatment in the prevention of breast cancer in humans.
